Cargando…

Decoy Plasminogen Receptor Containing a Selective Kunitz-Inhibitory Domain

[Image: see text] Kunitz domain 1 (KD1) of tissue factor pathway inhibitor-2 in which P2′ residue Leu17 (bovine pancreatic trypsin inhibitor numbering) is mutated to Arg selectively inhibits the active site of plasmin with ∼5-fold improved affinity. Thrombin cleavage (24 h extended incubation at a 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Yogesh, Vadivel, Kanagasabai, Schmidt, Amy E., Ogueli, Godwin I., Ponnuraj, Sathya M., Rannulu, Nalaka, Loo, Joseph A., Bajaj, Madhu S., Bajaj, S. Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985851/
https://www.ncbi.nlm.nih.gov/pubmed/24383758
http://dx.doi.org/10.1021/bi401584b
_version_ 1782311635943161856
author Kumar, Yogesh
Vadivel, Kanagasabai
Schmidt, Amy E.
Ogueli, Godwin I.
Ponnuraj, Sathya M.
Rannulu, Nalaka
Loo, Joseph A.
Bajaj, Madhu S.
Bajaj, S. Paul
author_facet Kumar, Yogesh
Vadivel, Kanagasabai
Schmidt, Amy E.
Ogueli, Godwin I.
Ponnuraj, Sathya M.
Rannulu, Nalaka
Loo, Joseph A.
Bajaj, Madhu S.
Bajaj, S. Paul
author_sort Kumar, Yogesh
collection PubMed
description [Image: see text] Kunitz domain 1 (KD1) of tissue factor pathway inhibitor-2 in which P2′ residue Leu17 (bovine pancreatic trypsin inhibitor numbering) is mutated to Arg selectively inhibits the active site of plasmin with ∼5-fold improved affinity. Thrombin cleavage (24 h extended incubation at a 1:50 enzyme-to-substrate ratio) of the KD1 mutant (Leu17Arg) yielded a smaller molecule containing the intact Kunitz domain with no detectable change in the active-site inhibitory function. The N-terminal sequencing and MALDI-TOF/ESI data revealed that the starting molecule has a C-terminal valine (KD1(L17R)-V(T)), whereas the smaller molecule has a C-terminal lysine (KD1(L17R)-K(T)). Because KD1(L17R)-K(T) has C-terminal lysine, we examined whether it could serve as a decoy receptor for plasminogen/plasmin. Such a molecule might inhibit plasminogen activation as well as the active site of generated plasmin. In surface plasmon resonance experiments, tissue plasminogen activator (tPA) and Glu-plasminogen bound to KD1(L17R)-K(T) (K(d) ∼ 0.2 to 0.3 μM) but not to KD1(L17R)-V(T). Furthermore, KD1(L17R)-K(T) inhibited tPA-induced plasma clot fibrinolysis more efficiently than KD1(L17R)-V(T). Additionally, compared to ε-aminocaproic acid KD1(L17R)-K(T) was more effective in reducing blood loss in a mouse liver-laceration injury model, where the fibrinolytic system is activated. In further experiments, the micro(μ)-plasmin–KD1(L17R)-K(T) complex inhibited urokinase-induced plasminogen activation on phorbol-12-myristate-13-acetate-stimulated U937 monocyte-like cells, whereas the μ-plasmin–KD1(L17R)-V(T) complex failed to inhibit this process. In conclusion, KD1(L17R)-K(T) inhibits the active site of plasmin as well as acts as a decoy receptor for the kringle domain(s) of plasminogen/plasmin; hence, it limits both plasmin generation and activity. With its dual function, KD1(L17R)-K(T) could serve as a preferred agent for controlling plasminogen activation in pathological processes.
format Online
Article
Text
id pubmed-3985851
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-39858512015-01-02 Decoy Plasminogen Receptor Containing a Selective Kunitz-Inhibitory Domain Kumar, Yogesh Vadivel, Kanagasabai Schmidt, Amy E. Ogueli, Godwin I. Ponnuraj, Sathya M. Rannulu, Nalaka Loo, Joseph A. Bajaj, Madhu S. Bajaj, S. Paul Biochemistry [Image: see text] Kunitz domain 1 (KD1) of tissue factor pathway inhibitor-2 in which P2′ residue Leu17 (bovine pancreatic trypsin inhibitor numbering) is mutated to Arg selectively inhibits the active site of plasmin with ∼5-fold improved affinity. Thrombin cleavage (24 h extended incubation at a 1:50 enzyme-to-substrate ratio) of the KD1 mutant (Leu17Arg) yielded a smaller molecule containing the intact Kunitz domain with no detectable change in the active-site inhibitory function. The N-terminal sequencing and MALDI-TOF/ESI data revealed that the starting molecule has a C-terminal valine (KD1(L17R)-V(T)), whereas the smaller molecule has a C-terminal lysine (KD1(L17R)-K(T)). Because KD1(L17R)-K(T) has C-terminal lysine, we examined whether it could serve as a decoy receptor for plasminogen/plasmin. Such a molecule might inhibit plasminogen activation as well as the active site of generated plasmin. In surface plasmon resonance experiments, tissue plasminogen activator (tPA) and Glu-plasminogen bound to KD1(L17R)-K(T) (K(d) ∼ 0.2 to 0.3 μM) but not to KD1(L17R)-V(T). Furthermore, KD1(L17R)-K(T) inhibited tPA-induced plasma clot fibrinolysis more efficiently than KD1(L17R)-V(T). Additionally, compared to ε-aminocaproic acid KD1(L17R)-K(T) was more effective in reducing blood loss in a mouse liver-laceration injury model, where the fibrinolytic system is activated. In further experiments, the micro(μ)-plasmin–KD1(L17R)-K(T) complex inhibited urokinase-induced plasminogen activation on phorbol-12-myristate-13-acetate-stimulated U937 monocyte-like cells, whereas the μ-plasmin–KD1(L17R)-V(T) complex failed to inhibit this process. In conclusion, KD1(L17R)-K(T) inhibits the active site of plasmin as well as acts as a decoy receptor for the kringle domain(s) of plasminogen/plasmin; hence, it limits both plasmin generation and activity. With its dual function, KD1(L17R)-K(T) could serve as a preferred agent for controlling plasminogen activation in pathological processes. American Chemical Society 2014-01-02 2014-01-28 /pmc/articles/PMC3985851/ /pubmed/24383758 http://dx.doi.org/10.1021/bi401584b Text en Copyright © 2014 American Chemical Society
spellingShingle Kumar, Yogesh
Vadivel, Kanagasabai
Schmidt, Amy E.
Ogueli, Godwin I.
Ponnuraj, Sathya M.
Rannulu, Nalaka
Loo, Joseph A.
Bajaj, Madhu S.
Bajaj, S. Paul
Decoy Plasminogen Receptor Containing a Selective Kunitz-Inhibitory Domain
title Decoy Plasminogen Receptor Containing a Selective Kunitz-Inhibitory Domain
title_full Decoy Plasminogen Receptor Containing a Selective Kunitz-Inhibitory Domain
title_fullStr Decoy Plasminogen Receptor Containing a Selective Kunitz-Inhibitory Domain
title_full_unstemmed Decoy Plasminogen Receptor Containing a Selective Kunitz-Inhibitory Domain
title_short Decoy Plasminogen Receptor Containing a Selective Kunitz-Inhibitory Domain
title_sort decoy plasminogen receptor containing a selective kunitz-inhibitory domain
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985851/
https://www.ncbi.nlm.nih.gov/pubmed/24383758
http://dx.doi.org/10.1021/bi401584b
work_keys_str_mv AT kumaryogesh decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain
AT vadivelkanagasabai decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain
AT schmidtamye decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain
AT ogueligodwini decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain
AT ponnurajsathyam decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain
AT rannulunalaka decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain
AT loojosepha decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain
AT bajajmadhus decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain
AT bajajspaul decoyplasminogenreceptorcontainingaselectivekunitzinhibitorydomain